Idiopathic interstitial pneumonia: Do community and academic physicians agree on diagnosis? by Flaherty, Kevin R. et al.
Idiopathic Interstitial Pneumonia
Do Community and Academic Physicians Agree on Diagnosis?
Kevin R. Flaherty1, Adin-Cristian Andrei2, Talmadge E. King, Jr.3, Ganesh Raghu4, Thomas V. Colby5,
Athol Wells6, Nadir Bassily7, Kevin Brown8, Roland du Bois6, Andrew Flint9, Steven E. Gay1, Barry H. Gross10,
Ella A. Kazerooni10, Robert Knapp11, Edmund Louvar7, David Lynch8, Andrew G. Nicholson6, John Quick12,
Victor J. Thannickal1, William D. Travis12, James Vyskocil7, Frazer A. Wadenstorer7, Jeffrey Wilt11,
Galen B. Toews1, Susan Murray2, and Fernando J. Martinez1
1Division of Pulmonary and Critical Care Medicine, University of Michigan Health System, Ann Arbor, Michigan; 2Department of Biostatistics,
University of Michigan School of Public Health, Ann Arbor, Michigan; 3University of California, San Francisco, San Francisco, California;
4University of Washington, Seattle, Washington; 5Mayo Clinic, Scottsdale, Arizona; 6Royal Brompton Hospital, London, United Kingdom;
7McLaren Regional Medical Center, Flint, Michigan; 8National Jewish Medical Center, Denver, Colorado; Departments of 9Pathology and
10Radiology, University of Michigan Health System, Ann Arbor, Michigan; 11Spectrum Health System, Grand Rapids, Michigan; and
12Memorial Sloan Kettering, New York, New York
Rationale: Treatment and prognoses of diffuse parenchymal lung
diseases (DPLDs) varies by diagnosis. Obtaining a uniform diagnosis
among observers is difficult.
Objectives: Evaluate diagnostic agreement between academic and
community-based physicians for patients with DPLDs, and deter-
mine if an interactive approach between clinicians, radiologists,
and pathologists improved diagnostic agreement in community
and academic centers.
Methods: Retrospective review of 39 patients with DPLD. A total of
19 participants reviewed cases at 2 community locations and 1
academic location. Information from the history, physical examina-
tion, pulmonary function testing, high-resolution computed tomog-
raphy, and surgical lung biopsy was collected. Data were presented
in the same sequential fashion to three groups of physicians on
separate days.
Measurements andMain Results: Each observer’s diagnosis was coded
into one of eight categories. A  statistic allowing for multiple raters
was used to assess agreement in diagnosis. Interactions between
clinicians, radiologists, and pathologists improved interobserver
agreement at both community and academic sites; however, final
agreementwas betterwithin academic centers ( 0.55–0.71) than
within community centers (  0.32–0.44). Clinically significant
disagreement was present between academic and community-
based physicians ( 0.11–0.56). Community physiciansweremore
likely to assign a final diagnosis of idiopathic pulmonary fibrosis
compared with academic physicians.
Conclusions: Significant disagreement exists in the diagnosis of
DPLD between physicians based in communities compared with
those in academic centers. Wherever possible, patients should be
referred to centerswith expertise in diffuse parenchymal lung disor-
ders to help clarify the diagnosis and provide suggestions regarding
treatment options.
Keywords: academic; community; diagnosis; nonspecific interstitial
pneumonia; usual interstitial pneumonia
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AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
The treatment and prognosis of idiopathic interstitial pneu-
monias varies by diagnosis. An interactive clinical–radio-
graphic–pathologic approach to diagnosis improves final
diagnostic agreement.
What This Study Adds to the Field
Significant disagreement exists in the diagnosis of idiopathic
interstitial pneumonia between physicians based in commu-
nity and those in academic centers. Patients with suspected
diffuse parenchymal lung disorders should be referred to
centers with expertise in this area to help clarify the diagno-
sis and for suggestions regarding treatment.
Histopathologic subsets of idiopathic interstitial pneumonia
(IIP) exhibit different prognoses (1–9). Therefore, an accurate
diagnosis is critical to themanagement of patients with IIP. Clinical
features, high-resolution computed tomography (HRCT) (10–14),
and surgical lung biopsy (SLB) (15) all play a role in establishing
a diagnosis. The American Thoracic Society/European Respira-
tory Society has recommended a dynamic, diagnostic, integrated
process in which clinicians, radiologists, and pathologists ex-
change information in the determination of a diagnosis (16). We
recently documented that such an approach among experts
leads to changes in the final diagnosis compared with individual
observers acting in isolation (17). In this study, we evaluated
the agreement in classification of patients with suspected IIP
in community and academic settings. As secondary goals, we
examined the influence of an iterative diagnostic approach on
diagnostic agreement in a community compared with an aca-
demic setting, and addressed features that influenced diagnostic
approaches.
METHODS
Patient Selection
Data from patients referred to the University of Michigan Specialized
Center of Research in the Pathobiology of Fibrotic Lung Disease be-
tween August 2002 and December 2003 were used for this study. Pa-
tients with suspected IIP were referred to the study center by partici-
pants in the University of Michigan Fibrotic Lung Disease Network
(see section before References). Through the course of evaluation, all
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patients underwent a history, physical examination, complete pulmo-
nary function testing, HRCT, and SLB. Patients without an HRCT
scan or an SLB were excluded.
Data Collection
A standard form was used to collect clinical information, including
symptoms, environmental exposures, comorbid illnesses, medications,
smoking history, family history, physical exam findings, and serologic
data. Pulmonary function data (spirometry, lung volumes, and diffusion
capacity for carbon monoxide) and HRCT within 6 months of SLB
were reviewed. Data from bronchoscopy (transbronchial biopsy and/
or bronchoalveolar lavage) were only available in a minority of patients
and were, therefore, not included in the data presented.
Study Organizational Scheme
Case information was provided to three groups (community 1, commu-
nity 2, and the University of Michigan) on separate days. Participants
at the University of Michigan were expert clinicians, radiologists, and
pathologists from five centers (within and outside the United States).
On average, participants at the University of Michigan had been in
practice longer and spend a greater amount of time in the evaluation
and treatment of patients with interstitial lung disease (see Table E1
in the online supplement). The cases were presented with the same
information and in the same order at each institution. We provided
participants incremental information through five stages (Figure 1), as
previously described (17). Briefly, clinicians and radiologists indepen-
dently reviewed clinical information, followed by HRCT, and then
discussed, as a group, the clinical and HRCT features (stages 1–3). As
this was occurring, the pathologists were independently reviewing SLB
specimens and assigning an independent histopathologic diagnosis. The
fourth step included a group (clinicians, radiologists, and pathologists)
discussion of the findings. During step 5, an attempt was made to reach
a consensus diagnosis.
Statistical Analysis
Each observer’s diagnosis was coded into one of eight categories: idio-
pathic pulmonary fibrosis (IPF), nonspecific interstitial pneumonia (NSIP),
bronchiolar/airway, hypersensitivity pneumonitis (HP), respiratory
bronchiolitis interstitial lung disease/desquamative interstitial pneumo-
nia (RBILD/DIP), cryptogenic organizing pneumonia (COP), intersti-
tial lung disease with suspected underlying collagen vascular disease
Figure 1. Schematic representation of the information presented to
each of the participants at each step of the study. Individuals made
their diagnostic decisions without conferring in steps 1 and 2 and indi-
vidually after conferring in steps 3–5 (modified from Reference 17).
HRCT  high-resolution computed tomography; SLB  surgical lung
biopsy.
(ILD/CVD), and “other.” McNemar tests were subsequently used to
test whether two probabilities of agreement conducted during different
steps or by different raters were equal. A  statistic allowing for multiple
raters was also used to assess agreement in diagnosis.  Scores are rated
as almost perfect agreement (above 0.8), substantial agreement (scores
between 0.6 and 0.8), moderate agreement (scores between 0.4 and
0.6), fair agreement (scores between 0.2 and 0.4), slight agreement
(scores between 0.0 and 0.2), and poor agreement (scores below 0.0)
(18). An estimating equation approach to the analysis of correlated
 statistics was used in comparisons of  statistics estimated throughout
the study and in producing confidence intervals for the  statistics (19).
SAS (SAS Institute, Cary, NC) macros, developed and described by
Gwet (20), were used to obtain the numerical characteristics of the
 statistics.
RESULTS
A total of 39 cases were evaluated by the community and aca-
demic specialists. Clinically significant differences in diagnoses
were present among the study participants.
Interobserver Agreement
Clinicians. Academic physicians displayed better agreement
compared with community physicians (Table 1; Figure 2). The
academic clinicians exhibited a very good agreement upon a
step 5 final diagnosis ( 0.71), as comparedwith the community
clinicians ( 0.44). The samewas true for all previous diagnosis
steps. This improved agreement occurred despite being more
numerous than their community counterparts (n  6 vs. n  3)
and, hence, less likely to reach agreement all else equal.  Scores
improved for both the community clinicians and academic clini-
cians asmore informationwas provided (steps 1–5), although this
was less impressive among the community participants (Table 1).
The fias fias fias fias final diagnosis agreement between academic
and community clinicians varied from 0.20 to 0.56 (Table 2)
Radiologists. There was greater interobserver agreement
among the academic radiologists than among the community
radiologists.  Scores failed to improve for both the academic
radiologists and community radiologists as more information
was provided (Table 1; Figure 2). The final diagnosis agreement
between the academic and the community radiologists was low
(range, 0–0.34 [Table 2]).
Pathologists. There was greater interobserver agreement
among the academic pathologists than among the community
pathologists.  Scores for academic pathologists were similar at
all stages of evaluation, whereas community pathologists dis-
played improvement in agreement after discussing the case with
clinicians and radiologists (Table 1; Figure 2). The final diagnosis
agreement between the academic and community pathologists
was low (range, 0.12–0.48 [Table 2]).
Intraobserver Agreement
In general,  scores for the clinicians appeared to be somewhat
lower between the first and second stages than between the
second and third stages, suggesting that clinical information al-
tered HRCT interpretation more than did interaction with the
radiologists (Figure 3). In addition, the  scores appeared lower
between the third and fourth stages than between the second
and third stages, confirming the influence of pathologic interpre-
tation on changing diagnoses.
Among radiologists, the provision of clinical information at
stage 2 appeared to have a greater effect on academic radiolo-
gists, as suggested by lower intraobserver agreement among these
participants between the first and second stages (Figure 3) com-
pared with community radiologists. Interaction with clinicians
(between second and third stages) led to few changes. The provi-
sion of pathologic information led to the greatest changes (stages
1056 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 175 2007
TABLE 1. INTEROBSERVER AGREEMENT  SCORE STRATIFIED BY CENTER TYPE AND
STEP OF THE EVALUATION PROCESS
Clinicians Radiologists Pathologists
Step Academic Community Academic Community Academic Community
1 0.28 (0.03) 0.20 (0.07) 0.59 (0.11) 0.38 (0.12) 0.57 (0.06) 0.14 (0.17)
2 0.32 (0.03) 0.23 (0.06) 0.41 (0.08) 0.34 (0.11) NA NA
3 0.37 (0.02) 0.27 (0.06) 0.45 (0.08) 0.40 (0.11) 0.53 (0.06) NA
4 0.62 (0.03) 0.47 (0.08) 0.55 (0.08) 0.31 (0.11) 0.53 (0.05) 0.14 (0.15)
5 0.71 (0.03) 0.44 (0.07) 0.55 (0.08) 0.32 (0.11) 0.57 (0.05) 0.41 (0.13)
Definition of abbreviation: NA  not available.
Values are  scores (SE).
3 to 4). Slight changes were seen in intraobserver agreement
among the participating pathologists with the provision of clini-
cal and radiologic information (Figure 3).
Comparison of Final Diagnoses
Total or near-total (all agree except one or two observers) agree-
ment was achieved in a minority of cases (Table 3). Most agree-
ment occurred with a diagnosis of IPF for both community and
academic physicians. Community-based physicians were more
likely to make a diagnosis of IPF than were academic-based
physicians.
We subsequently explored differences in diagnosis at a case-
by-case level. Cases were grouped (Figure 4) by final diagnosis
into cases in which the majority of observers felt the diagnosis
was IPF, a disagreement between IPF and HP, HP, CVD, NSIP,
disagreement between IPF and NSIP, bronchiolar/RBILD,
COP, and “other.” For cases in which a split diagnostic opinion
was present, there was a trend for community physicians to make
a diagnosis of IPF and for academic physicians to assign a non-
IPF diagnosis.
Final diagnosis favored IPF. In 13 cases, the final majority
diagnosis was IPF. In these cases, academic clinicians and radiol-
ogists were more likely to consider a diagnosis of NSIP or HP
Figure 2. Graphic representation of interobserver agreement () for
clinicians, radiologists, and pathologists within academic or community
centers at each step of the diagnostic evaluation. Academic clinicians,
n  6; community clinicians, n  3; academic radiologists, n  2;
community radiologists, n  2; academic pathologists, n  4; commu-
nity pathologists, n  2.
before the pathologic information compared with community
physicians. Interestingly, there was near-complete agreement
among community and academic pathologists at each stage. The
fact that two cases (351 and 357) had a history of bird exposure
did not seem to impact the diagnosis of IPF.
Final diagnosis split between IPF and HP. In three cases, there
was a split between a diagnosis of IPF versus HP. Academic
physicians seemed to favor a diagnosis of HP, and community
physicians seemed to favor a diagnosis of IPF. Two of these three
cases had a history of bird exposure. The listing of granulomas
as a feature by pathologists (data not shown) varied within
both academic and community pathologists, suggesting that
HRCT appearance played a role in the final diagnosis as aca-
demic radiologists, clinicians, and pathologists were more likely
to assign a final diagnosis of HP than were their community
counterparts.
Final diagnosis HP. In four cases, the majority consensus
diagnosis was HP. In these cases, the diagnosis appeared to
be driven by the finding of granulomas by pathologists, as the
prepathology diagnoses by clinicians and radiologists were ex-
tremely varied and only one case had a history of bird exposure.
Final diagnosis involved the consideration of CVD. In six cases,
observers raised the possibility of an underlying CVD contribut-
ing to the pulmonary findings. Clinical information for these
patients often included a known history of CVD or positive
serologies.
Final diagnosis NSIP or final diagnosis split between IPF and
NSIP. In two cases, the final majority diagnosis was NSIP, al-
though several observers selected IPF or HP as their first-choice
final diagnosis. In four cases, there was a split in final diagnosis
between IPF and NSIP. Academic clinicians and radiologists
were more likely to assign a diagnosis of NSIP, whereas their
community counterparts were more likely to assign a diagnosis
of IPF. In general, both community and academic pathologists
favored a diagnosis of IPF. These cases highlight the difficulty
in making a “consensus” diagnosis of NSIP, especially in a com-
munity setting.
Remaining cases. In the remaining cases, there were two cases
of COP, one case each of bronchiolar disease and RBILD, and
three cases with near-complete diagnostic disagreement.
DISCUSSION
Diffuse parenchymal lung diseases (DPLDs) are a diverse group
of disorders with varied prognoses and response to therapy.
Assigning a specific DPLD diagnosis to an individual patient is
difficult and, at times, imprecise. However, making an accurate
diagnosis, and, importantly, having a uniform diagnostic ap-
proach applied to patients wherever they are seen, is critical to
the study and application of clinical trial data to individual pa-
tients. We previously demonstrated that an integrated diagnostic
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TABLE 2. INTEROBSERVER AGREEMENT  SCORE FOR THE FINAL DIAGNOSIS BETWEEN
ACADEMIC- AND COMMUNITY-BASED CLINICIANS, RADIOLOGISTS, AND PATHOLOGISTS
Academic 1 Academic 2 Academic 3 Academic 4 Academic 5 Academic 6
Clinicians
Community 1 0.22 (0.10) 0.28 (0.10) 0.20 (0.10) 0.21 (0.11) 0.35 (0.11) 0.21 (0.10)
Community 2 0.40 (0.09) 0.39 (0.09) 0.38 (0.09) 0.40 (0.10) 0.50 (0.10) 0.25 (0,09)
Community 3 0.50 (0.09) 0.50 (0.09) 0.46 (0.09) 0.55 (0.09) 0.44 (0.09) 0.56 (0.09)
Radiologists
Radiologists
Community 1 0.23 (0.08) 0.34 (0.09) — — — —
Community 2 0.11 (0.09) 0.23 (0.10) — — — —
Pathologists
Community 1 0.40 (0.12) 0.12 (0.12) 0.26 (0.13) 0.23 (0.12) — —
Community 2 0.47 (0.10) 0.45 (0.10) 0.48 (0.11) 0.46 (0.10) — —
Values are  scores (SE).
approach involving expert clinicians, radiologists, and patholo-
gists results in an altered diagnosis compared with that of individ-
ual physicians working in isolation (17). In the current study,
we expand these findings by examining the diagnostic agreement
between community- and academic-based physicians using a dy-
namic interactive process involving pulmonary clinicians, radiol-
ogists, and pathologists. We demonstrate that: (1) clinically sig-
nificant disagreement exists regarding the diagnosis of IIP among
Figure 3. Graphic representation of intraobserver agreement () for
clinicians, radiologists, and pathologists within academic or community
centers between different steps in the diagnostic process. A high-level
 indicates little change in diagnosis between steps. For community
pathologists, the value at step 3/4 represents the change in diagnosis
from their individual histopathologic interpretation compared with the
diagnosis after discussing the clinical, radiographic, and histopathologic
information as a group. For academic pathologists, the value at step
2/3 represents the agreement between the individual pathologist’s in-
terpretation and the group pathology discussion; step 3/4 represents
the agreement between the group pathology diagnosis before and after
discussing the clinical, radiographic, and histopathologic information
as a group. For all participants, step 4/5 represents the agreement in
diagnosis from the group discussion (step 4) and final consensus (step
5). Academic clinicians, n  6; community clinicians, n  3; academic
radiologists, n  2; community radiologists, n  2; academic patholo-
gists, n  4; community pathologists, n  2.
academic-based clinicians and between community- and
academic-based physicians, with community physicians more
likely to make a diagnosis of IPF; (2) final diagnostic agreement
was higher between academic physicians comparedwith commu-
nity physicians; (3)most diagnostic agreement occurred for cases
of IPF; (4) most diagnostic discord occurred between cases of
IPF versus HP, IPF versus NSIP, and the potential influence of
CVD, with community-based physicians more likely to render
a diagnosis of IPF. These data highlight how an individual patient
with suspectedDPLD can have a significantly different diagnosis
depending on the physician and, particularly, the location of
evaluation. Although a combined clinical, radiographic, and
pathologic approach improves agreement, significant disagree-
ment still exists. These data highlight the need for better ways
to approach and classify patients with suspected DPLD.
Recent guidelines suggest that DPLDs, including IIPs, can
be separated based on clinical, radiographic, and histopathologic
criteria (16). The importance of “splitting” versus “lumping”
DPLDs stems from the varied etiologies, treatments, and prog-
noses associated with different diseases. Academic physicians
used a wider array of diagnoses compared with community-
based physicians who used a more consistent diagnosis of IPF.
In our series, 13 (33%) cases were believed to represent IPF by
a majority of both community- and academic-based physicians.
Importantly, community physicians made the diagnosis of IPF
in 11 additional cases, where the academic physicians believed
HP (n  3), NSIP (n  4), or CVD-associated (n  4) disease
TABLE 3. AGREEMENT IN FINAL DIAGNOSIS
IPF NSIP Bronchiolar HP RBILD Other COP CVD
All* 7 — — 1 — — 1 —
All  1† 5 — — 1 — — — —
All  2‡ 1 — — — — — —
Community clinicians 14 2 — 2 — — 2
Academic clinicians 12 1 1 4 1 — 1 3
Community radiologists 16 1 — 1 — — 1 1
Academic radiologists 8 4 1 6 2 1 2 3
Community pathologists 19 — — 3 — — 1 2
Academic pathologists 13 1 1 4 1 — 1 —
Definition of abbreviations: COP  cryptogenic organizing pneumonia; CVD 
collagen vascular disease; HP  hypersensitivity pneumonitis; IPF  idiopathic
pulmonary fibrosis; NSIP nonspecific interstitial pneumonia; RBILD respiratory
bronchiolitis interstitial lung disease.
* All observers were in agreement.
† All  1  all observers except 1 observer that disagreed.
‡ All – 2  all observers except 2 observers that disagreed.
Values are number of cases.
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Figure 4. Color and character represen-
tation of diagnosis for each case (Pt_code)
by observer. Columns headed with a “2”
represent the diagnosis before pathologic
information (for clinicians and radiolo-
gists) or clinical/HRCT information (for
pathologists). Columns headedwith a “5”
represent the final diagnosis after a clini-
cal/radiographic/pathologic discussion.
Each cell is letter/color coded (I/red  id-
iopathic pulmonary fibrosis [IPF]; N/light
blue  nonspecific interstitial pneumonia
[NSIP]; B/dark green airway/bronchiolar
disease;H/yellow hypersensitivity pneu-
monia [HP]; R/light green  respiratory
bronchiolitis interstitial lung disease
[RBILD]; O/orange  other; C/pink 
cryptogenic organizing pneumonia [COP];
S/dark blue  systemic collagen vascular
disease–associated interstitial lung dis-
ease). For example, community clinician
1 (CC1) initially diagnosed case 365 as
NSIP, but changed to a diagnosis of IPF
after a clinical/radiographic/pathologic
discussion. IIP  idiopathic interstitial
pneumonia.
was present. The importance of this finding is highlighted by
the different prognoses among these diagnoses, and the novel
therapeutic approaches currently under study based on biologi-
cal plausibility in IPF. The relative minority of IPF cases com-
pared with other IIPs in our series may reflect the requirement
for all cases to have both an HRCT and SLB; cases of IPF based
solely on definite HRCT criteria were excluded.
The current data document that the greatest disagreement
in diagnosis occurred between academic and community physi-
cians. However, significant disagreement was present even
within academic centers. The better agreement for academic
physicians likely reflects, at least in part, that these physicians
with an interest inDPLDhave collaborated on previous projects,
including the generation of consensus statements. This suggests
that more intense interaction between academic and community
physicians could improve the diagnostic agreement between
community and academic physicians, and should help standard-
ize the approach to the treatment and study of patients with
DPLD. In addition, the proportion of time devoted to clinical
management of DPLD is likely important, as the community
clinician who devoted the greatest time to the management of
these disorders exhibited greater agreement with his academic
counterparts.
We previously demonstrated that a dynamic, iterative ap-
proach to IIP diagnosis improves interobserver agreement
among expert clinicians, particularly in patients without IPF
(17). The current data highlight that a similar iterative approach
improves diagnostic agreement within community clinicians.
Two differences between community and academic physicians
were evident. Community clinicians’ agreement improved to a
lesser degree than that of academic clinicians, and the final diag-
nosis by community pathologists was more influenced by the
interaction with clinicians/radiologists than in the academic set-
ting. This suggests that the final diagnosis in an academic setting
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is driven by pathology compared with the clinician/radiologist
in the community setting. This latter observation could reflect
the relative expertise, and thus assertiveness, of community clini-
cians/radiologists compared with community pathologists in the
diagnosis of IIP. Pathology information appeared to influence
the diagnosis of some cases in both community and academic
centers, as the diagnosis of HP versus IPF seemed to correlate
more with the presence/absence of granulomas compared with
a clinical history of bird exposure.
Academic clinicians and radiologists used a wider array of
diagnoses before receiving pathology information. The findings
of subpleural, lower-lobe, honeycomb, and reticular changewith-
out micronodules, peribronchiolar nodules, consolidation, iso-
lated cysts, or a predominance of ground glass opacity have a
high positive predictive value for finding the histopathologic
pattern of usual interstitial pneumonia (UIP) on SLB (10, 11,
22). A recent, survey-based study suggested that 67% of clini-
cians would accept an HRCT diagnosis of IPF, particularly if
the observer had a higher self-rating of proficiency in reading
HRCT (23). It is possible that the academic clinicians and radiol-
ogists in our study were more stringent in their application of
these findings, and thus less likely to make a diagnosis of IPF
without a biopsy.
Our prospectively collected data suggest that pathologists will
consider clinical and radiologic data in rendering a final diagnosis
and emphasizes the need for pathologists to consider these data
in rendering a final diagnosis. This is supported by the decrease
in intraobserver agreement between stages with and without
clinical and radiologic information. This evaluative process was
seen among both academic and community-based pathologists.
Review of the individual patient data suggests that an exposure
history consistent with HP, or a history suggestive of a CVC,
was particularly likely to alter diagnosis, including away from a
diagnosis of IPF. Given the difference in survival characteristic
between IPF and connective tissue–associated UIP and chronic
HP (21), this point may have important clinical ramifications.
A limitation of this study is the lack of transbronchial biopsy
and/or bronchoalveolar lavage data for the majority of patients.
This absence reflects the practice pattern at the University of
Michigan and surrounding communities, where bronchoscopy is
used infrequently when a diagnosis of IIP (especially UIP or
NSIP) is considered. It is possible that rigorous collection of
bronchoscopy data could impact the final diagnostic impression.
Additional research is required to clarify the role of bronchos-
copy, relative HRCT, and SLB in the diagnostic algorithm for
patients with suspected IIP. Another limitation of this study is
the involvement of academic physicians who devote the majority
of their time to the study of interstitial lung disorders and, there-
fore, might not be representative of the whole “academic” physi-
cian group. This study was alsomostly based in the United States
and Europe, and might not fully represent the situation in other
countries.
Our data expand on previous literature on interobserver
agreement between clinicians, radiologists, and pathologists in
diagnosing IIPs. We confirm that an interactive approach be-
tween clinicians, radiologists, and pathologists improves interob-
server agreement. On the other hand, even with this approach,
significant disagreement exists within, and particularly between,
community and academic centers. The fact that community phy-
sicians were more likely to render a diagnosis of IPF has impor-
tant implications, as individual patients with HP, NSIP, or CVD-
associated ILDaremore likely to respond to immunosuppressive
treatment, whereas patients with IPF should be referred, when-
ever possible, for participation in therapeutic trials. Future ef-
forts are needed to bridge the gap of apparent discordance be-
tween community and academic experts in their diagnostic
proficiency. It is hoped that this will be accomplishedwith contin-
ued education, workshops, and increased interactions between
academic and community-based physicians. In the short-term,
these data suggest that, whenever possible, patients should be
referred to centers with expertise in diffuse parenchymal lung
disorders to help clarify the diagnosis and provide suggestions
regarding treatment options.
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